Ligand Pharmaceuticals (LGND) News Today → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free LGND Stock Alerts $86.42 +0.36 (+0.42%) (As of 10:57 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 20 at 6:24 AM | insidertrades.comInsider Selling: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Director Sells 934 Shares of StockMay 20 at 6:00 AM | investorplace.com3 Must-Buy Biotech Stocks Before the Summer Rally Kicks OffMay 19 at 5:46 AM | americanbankingnews.comOctavio Espinoza Sells 5,156 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) StockMay 19 at 5:46 AM | americanbankingnews.comOctavio Espinoza Sells 5,873 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) StockMay 17 at 10:35 PM | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Director Nancy Ryan Gray Sells 934 SharesLigand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) Director Nancy Ryan Gray sold 934 shares of the stock in a transaction on Thursday, May 9th. The stock was sold at an average price of $83.20, for a total transaction of $77,708.80. Following the sale, the director now directly owns 5,633 shares of the company's stock, valued at approximately $468,665.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.May 17 at 8:10 PM | investing.comLigand Pharmaceuticals director Nancy Gray sells shares worth over $77kMay 17 at 8:10 PM | investing.comLigand Pharmaceuticals CFO sells over $1.1 million in stockMay 17 at 6:36 AM | americanbankingnews.comMatthew E. Korenberg Sells 3,440 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) StockMay 16, 2024 | insidertrades.comInsider Selling: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Sells 3,440 Shares of StockMay 16, 2024 | finance.yahoo.comInsider Sale: President & Chief Operating Officer Matthew Korenberg Sells Shares of Ligand ...May 16, 2024 | marketbeat.comRussell Investments Group Ltd. Purchases 11,345 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Russell Investments Group Ltd. boosted its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 65.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 28,662 shares of the biotechnology company's stocMay 14, 2024 | markets.businessinsider.comLigand Moves to Strong Buy: Rationale Behind the UpgradeMay 14, 2024 | insidertrades.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Insider Andrew Reardon Sells 10,000 SharesMay 12, 2024 | americanbankingnews.comLigand Pharmaceuticals (NASDAQ:LGND) Rating Reiterated by HC WainwrightMay 9, 2024 | finance.yahoo.comLigand Pharmaceuticals First Quarter 2024 Earnings: EPS: US$4.86 (vs US$2.56 in 1Q 2023)May 8, 2024 | finance.yahoo.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call TranscriptMay 8, 2024 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Shares Up 7.3% Following Strong EarningsLigand Pharmaceuticals (NASDAQ:LGND) Trading Up 7.3% After Better-Than-Expected EarningsMay 8, 2024 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Ligand Pharmaceuticals (NASDAQ:LGND)HC Wainwright reaffirmed a "buy" rating and issued a $144.00 target price on shares of Ligand Pharmaceuticals in a report on Wednesday.May 8, 2024 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Updates FY 2024 Earnings GuidanceLigand Pharmaceuticals (NASDAQ:LGND) updated its FY 2024 earnings guidance. The company provided EPS guidance of 4.250-4.750 for the period, compared to the consensus estimate of 4.440. The company also issued revenue guidance of $130.0 millionillion-$142.0 millionillion, compared to the consensus estimate of $137.7 millionillion.May 8, 2024 | finance.yahoo.comLigand Pharmaceuticals Inc (LGND) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth ...May 8, 2024 | marketbeat.comFisher Asset Management LLC Increases Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Fisher Asset Management LLC boosted its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 48.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 49,297 shares of tMay 8, 2024 | finance.yahoo.comQ1 2024 Agenus Inc Earnings CallMay 7, 2024 | investorplace.comLGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | markets.businessinsider.comLigand Pharmaceuticals Inc Q1 Profit Increases, beats estimatesMay 7, 2024 | finance.yahoo.comLigand Pharmaceuticals Inc (LGND) Reports Mixed Q1 2024 Results: Misses Revenue Estimates but ...May 7, 2024 | seekingalpha.comLigand Pharmaceuticals Incorporated 2024 Q1 - Results - Earnings Call PresentationMay 7, 2024 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Announces Quarterly Earnings ResultsLigand Pharmaceuticals (NASDAQ:LGND - Get Free Report) released its earnings results on Tuesday. The biotechnology company reported $3.84 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.83 by $3.01. Ligand Pharmaceuticals had a net margin of 37.80% and a return on equity of 11.98%. The company had revenue of $30.90 million for the quarter, compared to the consensus estimate of $27.92 million. During the same period in the prior year, the company posted $1.96 EPS. The company's revenue was down 29.8% compared to the same quarter last year.May 7, 2024 | businesswire.comLigand Reports First Quarter 2024 Financial ResultsMay 7, 2024 | markets.businessinsider.comLigand Enters Into $100 Mln Royalty Financing Agreement With Agenus For BOT/BAL Clinical Dvpt.May 7, 2024 | businesswire.comLigand and Agenus Enter Into $100 Million Royalty Financing AgreementApril 30, 2024 | marketbeat.comLigand Pharmaceuticals (LGND) Set to Announce Earnings on TuesdayLigand Pharmaceuticals (NASDAQ:LGND) will be releasing earnings after the market closes on Tuesday, May 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=587752)April 25, 2024 | marketbeat.com47,703 Shares in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Acquired by Acuitas Investments LLCAcuitas Investments LLC acquired a new position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 47,703 shares of the biotechnology company's stock, valued at approximatelApril 23, 2024 | businesswire.comLigand to Report First Quarter 2024 Financial Results on May 7, 2024April 21, 2024 | marketbeat.comAllspring Global Investments Holdings LLC Has $2.66 Million Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Allspring Global Investments Holdings LLC increased its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 98.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investoApril 18, 2024 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Stock Price Down 5.2%Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Down 5.2%April 17, 2024 | finance.yahoo.comWall Street Analysts Predict a 45.56% Upside in Ligand (LGND): Here's What You Should KnowApril 13, 2024 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Sees Significant Drop in Short InterestLigand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) was the target of a significant drop in short interest during the month of March. As of March 31st, there was short interest totalling 672,100 shares, a drop of 23.3% from the March 15th total of 876,300 shares. Approximately 4.1% of the company's shares are short sold. Based on an average daily volume of 162,300 shares, the days-to-cover ratio is currently 4.1 days.April 12, 2024 | marketbeat.comSmith Graham & Co. Investment Advisors LP Has $5.94 Million Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Smith Graham & Co. Investment Advisors LP boosted its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 34.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 83,121April 10, 2024 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Purchased by Impax Asset Management Group plcImpax Asset Management Group plc boosted its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 11.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 205,208 shares of the biotechnology company's stoApril 9, 2024 | finance.yahoo.comCan Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Performance Keep Up Given Its Mixed Bag Of Fundamentals?April 8, 2024 | investorplace.com7 Small-Cap Stocks for the Thinking SpeculatorApril 8, 2024 | businesswire.comLigand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures ConferenceApril 5, 2024 | marketbeat.comQ2 2025 Earnings Forecast for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Issued By Zacks ResearchLigand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) - Zacks Research lifted their Q2 2025 earnings estimates for Ligand Pharmaceuticals in a research note issued on Tuesday, April 2nd. Zacks Research analyst S. Ganoria now expects that the biotechnology company will earn $1.01 per shaApril 4, 2024 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Shares Gap Up to $74.73Ligand Pharmaceuticals (NASDAQ:LGND) Shares Gap Up to $74.73April 4, 2024 | marketbeat.comLigand Pharmaceuticals Incorporated Expected to Post Q1 2025 Earnings of $0.98 Per Share (NASDAQ:LGND)Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) - Zacks Research increased their Q1 2025 EPS estimates for Ligand Pharmaceuticals in a research note issued to investors on Tuesday, April 2nd. Zacks Research analyst S. Ganoria now expects that the biotechnology company will post eaApril 2, 2024 | marketbeat.comChicago Capital LLC Lowers Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Chicago Capital LLC lessened its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 35.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 231,511 shares of the biotechnology company'sMarch 28, 2024 | finance.yahoo.comLigand (LGND) Down 15.5% Since Last Earnings Report: Can It Rebound?March 27, 2024 | msn.comLigand Pharmaceuticals gains amid bullish investor pitchMarch 26, 2024 | marketbeat.comPacer Advisors Inc. Raises Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Pacer Advisors Inc. lifted its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 59.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 325,727 shares of the biotechnology companMarch 21, 2024 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Purchased by Deutsche Bank AGDeutsche Bank AG grew its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 43.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 136,229 shares of the biotechnology company Get Ligand Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter. Email Address Warren Buffett's "mystery stock" (Ad)WARNING: Read This Before the Next Fed Meeting Investors are looking to the Fed with high hopes for interest rate relief. Unfortunately, many have no idea there's another major story unfolding right now, one that could be worth $40 trillion. This Wall Street millionaire just stepped forward with all the details, and how it could make some LGND Media Mentions By Week LGND Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LGND News Sentiment▼0.280.42▲Average Medical News Sentiment LGND News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LGND Articles This Week▼184▲LGND Articles Average Week Get Ligand Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: DVAX News Today MNKD News Today IRWD News Today INVA News Today OPK News Today GERN News Today ARCT News Today PRAX News Today NRIX News Today CMPS News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LGND) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersBill Gates is all about this tiny $2 stockTimothy SykesUrgent Nvidia WarningAltimetryThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarShocking: One AI startup's revenue could surge 4,735%Manward PressCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
